Publication | Open Access

Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma

Anti-tumor ResponseLymphoid NeoplasiaHematological MalignancySerum RituximabMedicineImmunologyTumor ImmunityRecurrent Low-gradeImmune Checkpoint InhibitorImmunotherapyOncologyRadiation OncologyCancer Research